Related Experiment Videos
Ampicillin versus cefamandole as initial therapy for community-acquired pneumonia
Abstract:
One hundred seven patients with community-acquired pneumonia thought to be of bacterial etiology by the admitting physician but whose initial sputum Gram stain was inadequate to direct specific therapy were randomized to receive either intravenous ampicillin or cefamandole as empiric therapy. Patients were excluded if the initial sputum Gram stain was highly suggestive of infection with Streptococcus pneumoniae, Staphylococcus aureus, or an enteric gram-negative bacillus. The two study groups had comparable demographic and presenting clinical features. The mean age of the patients evaluable for determination of clinical efficacy was 69 years, and greater than 75% had at least one serious underlying medical disorder. In the 90 evaluable patients, there were 11 therapeutic failures (12%), including 5 deaths (5%). Cefamandole, a broad-spectrum antibiotic, was not more efficacious than ampicillin in producing a satisfactory clinical response or in shortening the duration of parenteral therapy. Patients received an average of only 4 days of intravenous antibiotics before changeover to oral therapy and were hospitalized for a mean of 7 days. No patient experienced a relapse of pneumonia following successful completion of parenteral drug therapy. We conclude that cefamandole is not a more effective agent than ampicillin for empiric therapy of community-acquired bacterial pneumonia of uncertain etiology.
Insights
For community-acquired pneumonia, broad-spectrum cefamandole showed no advantage over ampicillin for empiric therapy when the bacterial cause was unclear. Both antibiotics demonstrated similar efficacy in treating patients with bacterial pneumonia.
Area of Science:
- Infectious Diseases
- Pharmacology
- Critical Care Medicine
Background:
- Community-acquired pneumonia (CAP) is a significant cause of morbidity and mortality.
- Empiric antibiotic selection is crucial when bacterial etiology is suspected but not confirmed.
- Initial sputum Gram stain inadequacy necessitates careful evaluation of antibiotic choices.
Purpose of the Study:
- To compare the efficacy of intravenous ampicillin versus cefamandole for empiric therapy of CAP.
- To evaluate clinical response and duration of parenteral therapy in patients with bacterial pneumonia of uncertain etiology.
- To assess the safety and effectiveness of cefamandole compared to ampicillin.
Main Methods:
- A randomized trial involving 107 patients with CAP of suspected bacterial origin.
- Exclusion criteria included Gram stain suggestive of specific pathogens (e.g., Streptococcus pneumoniae).
- Patients received either intravenous ampicillin or cefamandole, with outcomes assessed in 90 evaluable patients.
Main Results:
- Overall therapeutic failure rate was 12% (11 of 90 patients), including 5 deaths (5%).
- Cefamandole did not demonstrate superior efficacy to ampicillin in achieving clinical response or reducing parenteral therapy duration.
- Patients were hospitalized for a mean of 7 days, with an average of 4 days of intravenous antibiotics.
Conclusions:
- Cefamandole is not more effective than ampicillin for the empiric treatment of community-acquired bacterial pneumonia of uncertain etiology.
- Both ampicillin and cefamandole appear to be viable options for initial empiric therapy in this patient population.
- Further research may explore newer agents or combination therapies for resistant pathogens.